Specific amino acids in the critically ill patient--exogenous glutamine/arginine: a common denominator?
OBJECTIVE
Glutamine and arginine are both used as nutritional supplements in critically ill patients. Although glutamine has been shown to be beneficial for the metabolically stressed patient, considerations about arginine supplementation are not unanimously determined. Our aim is to review the current knowledge on the possible interplay between glutamine and arginine generation in the stressed patient and to elaborate on whether these amino acids may function as a common denominator. Because glutamine can be given by the parenteral and enteral routes, possible different actions on the metabolic fate (e.g., generation of citrulline) with both routes are analyzed.


METHODS
A summary of data on the clinical effect of glutamine and arginine metabolism is given, incorporating data on glutamine and arginine supplementation. Differences between the route of administration, parenteral or enteral, and the molecular form of supplied glutamine, free or as dipeptide, on citrulline generation by the gut and production of arginine are discussed.


RESULTS
Glutamine and arginine influence similar organ systems; however, they differ in their targets. For example, glutamine serves as fuel for the immune cells, increases human leukocyte antigen-DR expression on monocytes, enhances neutrophil phagocytosis, and increases heat shock protein expression. Arginine affects the immune system by stimulating direct or indirect proliferation of immune cells. This indirect effect is possibly mediated by nitric oxide, which also enhances macrophage cytotoxicity. Furthermore, glutamine serves as a precursor for the de novo production of arginine through the citrulline-arginine pathway. Glutamine has shown to be beneficial in the surgical and critically ill patient, whereas arginine supplementation is still under debate. The route of glutamine administration (parenteral or enteral) determines the effect on citrulline and on the de novo arginine generation. There is a marked difference between the administration of free glutamine and dipeptide enterally or parenterally. Splanchnic extraction of the hydrolyzed glutamine in mice when administering the dipeptide enterally is higher compared with administering free glutamine from the enteral site. In patients, splanchnic extraction of the dipeptide given enterally is 100% when comparing supplementation of the dipeptide intravenously.


CONCLUSIONS
The beneficial effects of free glutamine or dipeptide may depend on the route of administration but also on the metabolic fate of amino acids generated (e.g., citrulline, arginine). Glutamine serves as a substrate for de novo citrulline and arginine synthesis. More research needs to be done to establish the direct clinical relevance of the different metabolic pathways. Future perspectives might include combining enteral and parenteral routes of administrating free glutamine or dipeptide.
Vermeulen
Mechteld A R
MA
Department of Surgery, VU University Medical Center, Amsterdam, The Netherlands.
van de Poll
Marcel C G
MC
Ligthart-Melis
Gerdien C
GC
Dejong
Cornelis H C
CH
van den Tol
M Petrousjka
MP
Boelens
Petra G
PG
van Leeuwen
Paul A M
PA
D000136:Acid-Base Equilibrium; D000818:Animals; D001120:Arginine / Q000378:metabolism* / Q000627:therapeutic use*; D002956:Citrulline / Q000378:metabolism; D016638:Critical Illness; D004151:Dipeptides / Q000627:therapeutic use; D004750:Enteral Nutrition; D041981:Gastrointestinal Tract / Q000378:metabolism; D005973:Glutamine / Q000378:metabolism* / Q000627:therapeutic use*; D005978:Glutathione / Q000096:biosynthesis; D006801:Humans; D018384:Oxidative Stress; D010288:Parenteral Nutrition; D013654:Taurine / Q000096:biosynthesis
D004151:Dipeptides; D005973:Glutamine; D013654:Taurine; D002956:Citrulline; D001120:Arginine; D005978:Glutathione; C054122:alanylglutamine